Moderna Sinks on AstraZeneca Covid-19 Vaccine Progress, JPMorgan Downgrade
Investing.com
Published Jul 20, 2020 09:53AM ET
Updated Jul 20, 2020 10:26AM ET
By Christiana Sciaudone
Investing.com -- Moderna (NASDAQ:MRNA) dropped 14% after AstraZeneca (NYSE:AZN) and Oxford University said their vaccine candidate showed promise.
The AstraZeneca-Oxford vaccine, AZD1222, is safe and produced an immune response in early-stage clinical trials in healthy volunteers, Reuters reported, citing data from The Lancet. No serious side effects were reported.
JPMorgan (NYSE:JPM) downgraded Moderna, which is working on a separate vaccine candidate, today on a high valuation, to neutral from overweight, The Street reported. Analyst Cory Kasimov boosted his one-year price target to $89 from $60.
Moderna has surged in recent months on vaccine news, quadrupling to more than $80 since March.
Moderna’s vaccine, mRNA-1273, elicited antibodies in all people tested in an initial safety trials, Bloomberg reported last week, though there was a high rate of side effects, with three of 45 people facing severe reactions. Moderna should begin a Phase 3 trial on July 27, The Street said.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.